

Express Mail Label No: EL 926059820 US
Date of Deposit: February 24, 2004

DOCKET NO: P0453.70113US04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Foss, et al.
Serial No: Not yet assigned
Confirmation No: Not yet assigned
Filed: February 12, 2004
For: ORAL USE OF METHYLNALTREXONE AND RELATED
COMPOUNDS TO TREAT CONSTIPATION IN
CHRONIC OPIOID USERS
Examiner: Not yet assigned
Art Unit: Not yet assigned

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement is being filed along with a continuation application.

PART II: Information Cited

Applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicants hereby makes the following additional information of record in the above-identified application.

The following co-pending applications that may contain subject matter related to this application are enclosed unless the earlier application is identified herein and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application:

| Serial No. | Filing Date | Inventor(s) | Docket No. |
|---------------|-------------------|----------------|------------------|
| Not yet known | February 24, 2004 | Foss et al. | P0453.70113US03 |
| Not yet known | February 12, 2004 | Foss et al. | P0453.70113US02 |
| Not yet known | February 12, 2004 | Foss et al. | P0453.70113US01 |
| 10/163,482* | June 5, 2002 | Moss et al. | P0453.70109US00 |
| 10/278,630* | October 23, 2002 | Foss et al. | P0453.70110.US00 |
| 10/358,560* | February 4, 2003 | Foss et al. | P0453.70114US00 |
| 60/461,611* | April 8, 2003 | Sanghvi et al. | P0453.70115US00 |
| 60/461,608* | April 8, 2003 | Boyd et al. | P0453.70112US00 |
| 60/461,585* | April 8, 2003 | Sanghvi et al. | P0453.70116US00 |

*A copy of this application is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/862,169, filed May 21, 2002, and prior application, Serial No. 10/278,630, filed October 23, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

Serial No.: not yet known

- 3 -

Art Unit: not yet known

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Foss, et al., *Applicant*

By: Edward R. Gates
Edward R. Gates
Reg. No. 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. P0453.70113US04
Date: February 24, 2004
x02/24/04

| | | | | | | | |
|---|---|----|---|--------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: Not yet known | | ATTY. DOCKET NO.: P0453.70113US04 | |
| | | | | FILING DATE: February 24, 2004 | | CONFIRMATION NO.: | |
| | | | | APPLICANT: Foss, et al. | | | |
| | | | | GROUP ART UNIT: Not yet known | | EXAMINER: Not yet known | |
| Sheet | 1 | of | 4 | | | | |

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YYYY |
|------------------------|-------------|----------------------|--------------|--|--|
| | | Number | Kind Code | | |
| | *A1 | 2001/0018413 | A1 | Crain, <i>et al.</i> | 08-30-2001 |
| | *A2 | 2002/0028825 | A1 | Foss, <i>et al.</i> | 03-07-2002c |
| | *A3 | 2001/0033865 | A1 | Oshlack, <i>et al.</i> | 10-25-2001 |
| | *A4 | 2001/0036476 | A1 | Oshlack, <i>et al.</i> | 11-01-2001 |
| | *A5 | 2001/0047005 | A1 | Farrar, <i>et al.</i> | 11-29-2001 |
| | *A6 | 4,176,186 | | Goldberg, <i>et al.</i> | 11-27-1979 |
| | *A7 | 4,719,215 | | Goldberg | 01-12-1988 |
| | *A8 | 4,861,781 | | Goldberg | 08-29-1989 |
| | *A9 | 4,987,136 | | Kreek, <i>et al.</i> | 01-22-1991 |
| | *A10 | 5,102,887 | | Goldberg | 04-07-1992 |
| | *A11 | 5,270,328 | | Cantrell, <i>et al.</i> | 12-14-1993 |
| | *A12 | 5,472,943 | | Crain, <i>et al.</i> | 12-05-1995 |
| | *A13 | 5,512,578 | | Crain, <i>et al.</i> | 04-30-1996 |
| | *A14 | 5,767,125 | | Crain, <i>et al.</i> | 06-16-1998 |
| | *A15 | 5,811,451 | | Minoia, <i>et al.</i> | 09-22-1998 |
| | *A16 | 5,866,164 | | Kuczynski, <i>et al.</i> | 02-02-1999 |
| | *A17 | 5,958,452 | | Oshlack, <i>et al.</i> | 09-28-1999 |
| | *A18 | 5,972,954 | | Foss, <i>et al.</i> | 10-26-1999 |
| | *A19 | 6,096,756 | | Crain, <i>et al.</i> | 08-01-2000 |
| | *A20 | 6,194,382 | B1 | Crain, <i>et al.</i> | 02-27-2001 |
| | *A21 | 6,261,599 | B1 | Oshlack, <i>et al.</i> | 07-17-2001 |
| | *A22 | 6,274,591 | B1 | Foss, <i>et al.</i> | 08-14-2001 |
| | *A23 | 6,395,705 | B2 | Crain, <i>et al.</i> | 05-28-2002 |
| | *A24 | 6,419,959 | B1 | Walter, <i>et al.</i> | 07-16-2002 |
| | *A25 | 6,451,806 | B2 | Farrar | 09-17-2002 |
| | *A26 | 6,559,158 | B1 | Foss, <i>et al.</i> | 05-06-2003 |
| | *A27 | 6,608,075 | B1 | Foss, <i>et al.</i> | 08-19-2003 |
| | *A28 | RE36,547 | | Crain, <i>et al.</i> | 02-01-2000 |
| | *A29 | 2002/0188005 | A1 | Farrar, <i>et al.</i> | 12-12-2002 |

| | | | | | | | |
|---|---|----|---|--------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: Not yet known | | ATTY. DOCKET NO.: P0453.70113US04 | |
| | | | | FILING DATE: February 24, 2004 | | CONFIRMATION NO.: Not yet known | |
| | | | | APPLICANT: Foss, et al. | | | |
| | | | | GROUP ART UNIT: Not yet known | | EXAMINER: Not yet known | |
| Sheet | 2 | of | 4 | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|---------------------|----------|-------------------------|-----------|-----------|---|--|-------------------|
| | | Office/Country | Number | Kind Code | | | |
| | *B1 | AU | 610,561 | | Shelley | 08-17-1988 | |
| | *B2 | CA | 1,315,689 | | The University of Chicago | 04-06-1993 | |
| | *B3 | EP | 0278821 | A1 | Shelly (Abstract) | 08-17-1988 | |
| | *B4 | EP | 0352361 | A1 | The Rockefeller University | 01-31-1990 | |
| | *B5 | EP | 278,821 | A1 | Marc Yves Shelly (Derwent Abstract) | 08-17-1988 | |
| | *B6 | EP | 306,575 | B1 | The Univ. of Chicago | 03-15-1989 | |
| | *B7 | EP | 352,361 | A1 | The Rockefeller University | 01-31-1990 | |
| | *B8 | EP | 760,661 | B1 | Minoia, <i>et al.</i> | 12-30-1998 | |
| | *B9 | JP | 2,625,457 | B2 | Goldberg (Derwent Abstract) | 07-02-1997 | |
| | *B10 | NZ | 222,911 | | The Univ. of Chicago | 12-14-1987 | |
| | *B11 | WO | 83/03197 | A1 | The Rockefeller University | 09-29-1983 | |
| | *B12 | WO | 88/05297 | A1 | Shelly | 07-28-1988 | |
| | *B13 | WO | 95/31985 | A2 | Minoia, <i>et al.</i> | 11-30-1995 | |
| | *B14 | WO | 97/33566 | | Alza Corp. | 09-18-1997 | |
| | *B15 | WO | 98/25613 | | Klinge Pharma GmbH | 06-18-1998 | yes |
| | *B16 | WO | 01/13909 | A2 | Critical Care Pharm. | 03-01-2001 | |
| | *B17 | WO | 01/37785 | A2 | Adolor Corp. | 05-31-2001 | |
| | *B18 | WO | 01/41705 | A2 | Adolor Corp. | 06-14-2001 | |
| | *B19 | WO | 01/42207 | A2 | Adolor Corp. | 06-14-2001 | |
| | *B20 | WO | 01/85257 | A2 | Pain Therapeutics, Inc.. | 11-15-2001 | |
| | *B21 | WO | 02/060870 | A2 | Adolor Corp. | 08-08-2002 | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|---------------------|---------|---|-------------------|
| | *C1 | AKINBAMI, <i>et al.</i> , <i>Neuroendocrinology</i> , (1994), 59(4), 343-348 | |
| | *C2 | AMIN, <i>et al.</i> , <i>Anesth. Analg.</i> (1994), 78(4), 701-5 | |
| | *C3 | AMIR, <i>Brain Res.</i> (1984) 297:187-90. | |
| | *C4 | AMIR, <i>et al.</i> , <i>Arch. Toxicol. Suppl.</i> , (1983), 6, 261-5 | |
| | *C5 | ARGENTIERI, <i>et al.</i> , <i>Brain Res.</i> (1983), 277(2), 377-9 | |
| | *C6 | BARATTI, <i>et al.</i> , <i>Methods Find. Exp. Clin. Pharmacol.</i> , (1990), 12(7), 451-6 | |
| | *C7 | BEDINGFIELD, <i>et al.</i> , <i>Alcohol</i> 15 (1): (1998), p51-54 | |
| | *C6 | BIANCHETTI, <i>et al.</i> , <i>Life Sciences</i> (1983) 33(1), 415-18 | |
| | *C9 | BIANCHI, <i>et al.</i> , <i>Life Sci.</i> , (1982), 30(22), 1875-83 | |
| | *C10 | BLANK, <i>et al.</i> , <i>Life Sciences.</i> (1986), 39(17), 1493-9 | |
| | *C11 | BROWN, <i>et al.</i> , <i>Brain Res.</i> , (1981), 221(2), 432-6 | |
| | *C12 | BROWN, <i>et al.</i> , <i>Neuropharmacology</i> (1983), 3A (22), 317-21 | |
| | *C13 | CALCAGNETTI, <i>Pharmacol Biochem Behav</i> 1987 Jul;27(3):529-31 (Abstract only) | |

| | | | | | | | |
|---|---|----|---|--------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: Not yet known | | ATTY. DOCKET NO.: P0453.70113US04 | |
| | | | | FILING DATE: February 24, 2004 | | CONFIRMATION NO.: Not yet known | |
| | | | | APPLICANT: Foss, et al. | | | |
| | | | | GROUP ART UNIT: Not yet known | | EXAMINER: Not yet known | |
| Sheet | 3 | of | 4 | | | | |

| | | | |
|------|---|--|--|
| *C14 | CHANG, et al., <i>J. Pharmacol. Exp. Ther.</i> (1984), 228(2), 364-9 | | |
| *C15 | CULPEPPER, et al., <i>Clinical Trials and Therapeutics</i> (1992) 52, 90-95 | | |
| *C16 | EISENBERG, <i>Life Sciences</i> , (1984), 34(12), 1185-91 | | |
| *C18 | FERNANDEZ-TOME, et al., <i>Pharmacol. Biochem. & Behavior</i> (1988) 29, 387-392 | | |
| *C19 | FOSS, <i>Am. Journal of Surgery</i> (2001) 182, 195-265 | | |
| *C20 | FOSS, et al., <i>Anesthesiology</i> , (1995), 83(3A), p. A361 | | |
| *C21 | FOSS, et al., <i>Cancer Chemother. Pharmacol.</i> (1998), 42(4), 287-291 | | |
| *C22 | FOSS, et al., <i>J. Clin. Pharmacol.</i> , (1997), 37(1) 25-30 | | |
| *C23 | FOSS, et al., <i>J. Clin. Pharmacol.</i> (1993), 33(8), 747-51 | | |
| *C24 | FOSS, et al., <i>Life Sciences</i> 59(15), (1996), p. PL235-PL238 | | |
| *C25 | FRANCE, et al., <i>Neuropharmacology</i> (1987), 26(6), 541-8 | | |
| *C26 | FRANCE, et al., <i>Pharmacol. Biochem. & Behavior</i> (1985) 23, 731-736 | | |
| *C27 | FRIEDMAN, et al., <i>Ann. Pharmacother.</i> , (2001), 35(1) 85-91 | | |
| *C28 | GMEREK, et al., <i>J. Pharmacol. Exp. Ther.</i> (1986), 236(1), 8-13 | | |
| *C29 | HEIN, et al., <i>J. Pharmacol. and Exper. Therapeutics</i> (1981), 218(1), 7-15 | | |
| *C30 | JALOWIEC, et al., <i>Pharmacol. Biochem. & Behav.</i> , (1989), 33(3), 697-700 | | |
| *C31 | JANCOVIC and RADULOVIC., <i>Immunopharmacology</i> (1994), 28, 105-112 | | |
| *C32 | KIM, et al., <i>Chromatographia</i> , (1989), 28(7-8), 359-63 | | |
| *C33 | KOBISH, et al., <i>Society for Neuroscience Abstracts</i> , (2001)27 (2), 2407 | | |
| *C34 | KOBYLECKI, et al., <i>Journal of Medicinal Chemistry</i> (1982), 25 (11) 1278-80 | | |
| *C35 | KOCZKA, et al., <i>Acta Chimica Academica Scien. Hung.</i> (1967) 51(4), 393-02 | | |
| *C36 | KOOB, et al., <i>J. Pharmacol. Exp. Ther.</i> (1984), 229(2), 481-6 | | |
| *C37 | KOTAKE, et al., <i>Xenobiotica</i> , 1989, 19(11), 1247-54 | | |
| *C38 | LEANDER, et al., <i>J. Pharmacol. Exp. Ther.</i> (1983), 224(1), 89-94 | | |
| *C39 | LITTLE, et al., <i>Society for Neuroscience Abstracts</i> , 27 (2); 2001, p. 2407 | | |
| *C40 | LYDON, et al., <i>European Journal of Anesthesiology</i> , 18 (Supplement 21), p. 92, 2001 (Abstract) | | |
| *C41 | LYSLE, et al., <i>Brain, Behavior and Immun.</i> (1992) 6, 179-188 | | |
| *C42 | MAGNAN et al., <i>Naunyn Schmiedeberg's Arch Pharmacol.</i> (1982) 319(3), 197-205 | | |
| *C43 | MANARA, et al., <i>Adv. Endog. Exog. Opioids, Poroc. Int. Narc. Res. Conf.</i> , 12th (1981), 402-4 | | |
| *C44 | MANARA, et al., <i>Ann. Rev. Pharmacol. Toxicol.</i> (1985) 25, 249-73 | | |
| *C45 | MICKLEY, et al., <i>Physiology & Behavior</i> , 1985, 35(2), p. 249-53 | | |
| *C46 | MISRA, et al., <i>J. Pharm. Pharmacol.</i> (1987), 39(3), 225-7 | | |
| *C47 | MOERMAN, et al., <i>Acta Anesthesiologica Belgica</i> (1995), 3-4 (46) p. 127-32 | | |
| *C48 | MOSS, et al., <i>N. Engl. J. Med.</i> , (2002) 346 (6), 455 | | |
| *C49 | MUCHA, <i>Brain Research</i> (1987) 418, 214-220 | | |
| *C50 | MUCHA, <i>Life Sci.</i> (1989), 45, p. 671-678 | | |
| *C51 | MURPHY, et al., <i>Anesthesiology</i> (1999) 91 (3A), A349, (Abstract) | | |
| *C52 | MURPHY, et al., <i>Anesthesiology</i> , (1997), 87(4), 765-770 | | |
| *C53 | MURPHY, et al., <i>Br. J. Anaesth.</i> (2001), 86(1) 120-122 | | |
| *C54 | MURPHY, et al., <i>J. Cardiovasc. Pharmacol.</i> , 1999, 33(1) 122-125 | | |
| *C55 | NARANJO, et al., <i>Life Sciences</i> (1986) 38(21) p. 1923-30 | | |
| *C56 | NELSON, <i>Dissertation Abstracts International</i> , (62/03-B), p. 1635 (Abstract) | | |
| *C57 | ODIO, et al., <i>Pharmacology Biochemistry & Behavior</i> , (1990), 35(4) 963-9 | | |
| *C58 | Oncology (1996) 10(12):1880. (No authors listed) | | |
| *C59 | OSINSKI, et al., <i>J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.</i> (2002) 780(2), 251-259 | | |
| *C60 | PAPPAGALLO, <i>Am. Journal of Surgery</i> (2001) (Supp. to 11/01) 182, 11S-18S | | |

| | | | | | | | |
|---|---|----|---|--------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: Not yet known | | ATTY. DOCKET NO.: P0453.70113US04 | |
| | | | | FILING DATE: February 24, 2004 | | CONFIRMATION NO.: Not yet known | |
| | | | | APPLICANT: Foss, et al. | | | |
| | | | | GROUP ART UNIT: Not yet known | | EXAMINER: Not yet known | |
| Sheet | 4 | of | 4 | | | | |

| | | | |
|------|---|--|--|
| *C61 | POWELL, et al., <i>J. Pharmacol. & Exp. Therapeutics</i> (2002) 300(2), 588-596 | | |
| *C62 | QUOCK, et al, <i>J. Bioelectr.</i> (1986), 5(1), 35-46 | | |
| *C63 | QUOCK, et al., <i>Life Sciences</i> , (1985), 37(9), 819-26 | | |
| *C64 | QUOCK, et al., <i>Prog. Neuro. Psychopharmacol. Biol. Psychiatry</i> (1985), 9(3), 239-43 | | |
| *C65 | RAMABADRAN, <i>Life Sciences</i> , 1982, 31(12-13), 1253-6 | | |
| *C66 | ROBINSON, et al., <i>The Lancet</i> (1991) 338, 581-582 | | |
| *C67 | RUSSELL, et al., <i>Eur. J. Pharmacol.</i> (1982), 78(3), 255-61 | | |
| *C68 | SCHAEFER, et al., <i>Pharmacol. Biochem. Behav.</i> (1985), 23(5), 797-802 | | |
| *C69 | SCHMIDHAMMER, et al., <i>Helv. Chim. Acta</i> (1994), Vol. 77, No. 6, p. 1585-9 | | |
| *C70 | SCHMIDHAMMER, et al., <i>Helv. Chim. Acta.</i> (1993) No. 1, p. 476-80 | | |
| *C71 | SCHOLZ, 2000, 63 (6) p. 103 | | |
| *C72 | SCHREIER, et al., <i>Proc. West. Pharmacol. Soc.</i> (1982), 25, 151-4 | | |
| *C73 | SOLVASON, et al., <i>Brain, Behav., Immun.</i> (1989), 3(3), 247-262 | | |
| *C74 | SWAN, et al., <i>AIDS Research</i> , NIDA Notes, (1995), 10(3), 1-6 | | |
| *C75 | SYKES, <i>The Lancet</i> (1991), 337, 1475 | | |
| *C76 | THOMPSON, et al., <i>Brain Res.</i> (1996) 743, 184-201 | | |
| *C77 | UKAI, et al., <i>Psychopharmacology</i> (1987), 91(3), 279-84 | | |
| *C78 | VALENTINO, et al., <i>J. Pharmacol. Exp. Ther.</i> , (1981), 217(3), 652-9 | | |
| *C79 | VALENTINO, et al., <i>Life Sciences.</i> , (1983), 32(25), 2887-96 | | |
| *C80 | WALKER, et al., <i>Psychopharmacology</i> (1991), 104(2), p. 164-6 | | |
| *C81 | WARREN et al., <i>J. Pharmacol. Exp. Ther.</i> (1985), 235(2), p. 412-17 | | |
| *C82 | WILLETTE, et al., <i>Res. Commun. Subst. Abuse</i> (1983), 4(4), 325-37 | | |
| *C83 | YUAN et al., <i>Drug Dev. Res.</i> (2000) 50(2), 133-141 | | |
| *C84 | YUAN et al., <i>Neuropharmacology</i> (March 1999), 38(3) 425-432 | | |
| *C85 | YUAN, et al., <i>Anesthesiology</i> , Sept. (1995), 83 (3A), p A358 (Abstract) | | |
| *C86 | YUAN, et al., <i>Anesthesiology</i> , Sept. (1995), 83 (3A), p A360 (Abstract) | | |
| *C87 | YUAN, et al., <i>Anesthesiology</i> , Sept. (1999), 91 (3A) p. A349 (Abstract) | | |
| *C88 | YUAN, et al., <i>Anesthesiology</i> , Sept. (1999), 91 (3A) p. A973 (Abstract) | | |
| *C89 | YUAN, et al., <i>Clin. Pharmacol. Ther.</i> (2000), 67(4) 398-404 | | |
| *C90 | YUAN, et al., <i>Clin. Pharmacol. Ther.</i> (1997), 61(4), 467-475 | | |
| *C91 | YUAN, et al., <i>Clin. Pharmacol., Ther.</i> , (1996), 59(4), 469-475 | | |
| *C92 | YUAN, et al., <i>Clinical Pharmacology & Therapeutics</i> (1995) 57(2), p. 138 | | |
| *C93 | YUAN, et al., <i>Drug Alcohol Depend.</i> (1998), 52(2), 161-165 | | |
| *C94 | YUAN, et al., <i>European Journal of Pharmacology</i> (1995), 276 p. 107-111 | | |
| *C95 | YUAN, et al., <i>J. Pharmacol. Exp. Ther.</i> (US)300 (1), 2002, pp. 118-123 | | |
| *C96 | YUAN, et al., <i>JAMA</i> 284, No. 11, (2000), p 1383-1384 | | |
| *C97 | YUAN, et al., <i>JAMA</i> , (2000), 283 (3), 367-372 | | |
| *C98 | YUAN, et al., <i>Pain</i> (1999) 83, 631-635 | | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/358,560, filed February 4, 2003, and prior application, Serial No. 10/278,630, filed October 23, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]